Published in J Virol on February 01, 1999
Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol (1999) 4.57
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol (2000) 3.50
Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol (2003) 2.91
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol (2001) 2.31
The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577. J Virol (2000) 2.15
Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J Virol (2001) 1.76
Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res (2007) 1.47
The ORF45 protein of Kaposi's sarcoma-associated herpesvirus is associated with purified virions. J Virol (2003) 1.41
Mass spectrometric analyses of purified rhesus monkey rhadinovirus reveal 33 virion-associated proteins. J Virol (2006) 1.26
Poly(ADP-ribose) polymerase 1 and Ste20-like kinase hKFC act as transcriptional repressors for gamma-2 herpesvirus lytic replication. Mol Cell Biol (2003) 1.21
Dissection of the Kaposi's sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J Virol (2004) 1.19
Intracellular localization map of human herpesvirus 8 proteins. J Virol (2007) 1.16
Kaposi's sarcoma-associated herpesvirus OX2 glycoprotein activates myeloid-lineage cells to induce inflammatory cytokine production. J Virol (2002) 1.13
Kinetics of expression of rhesus monkey rhadinovirus (RRV) and identification and characterization of a polycistronic transcript encoding the RRV Orf50/Rta, RRV R8, and R8.1 genes. J Virol (2002) 1.09
Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res (2010) 1.09
Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma. J Virol (2000) 1.09
Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol (1999) 1.07
Suppression of tetradecanoyl phorbol acetate-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus by K1 signal transduction. J Virol (2002) 1.02
Human herpesvirus 8--a novel human pathogen. Virol J (2005) 1.00
Kaposi's sarcoma-associated herpesvirus virions inhibit interferon responses induced by envelope glycoprotein gpK8.1. J Virol (2006) 0.93
The bovine herpesvirus 4 Bo10 gene encodes a nonessential viral envelope protein that regulates viral tropism through both positive and negative effects. J Virol (2010) 0.91
New immunofluorescence assays for detection of Human herpesvirus 8-specific antibodies. Clin Diagn Lab Immunol (2000) 0.85
Tracking expression and subcellular localization of RNA and protein species using high-throughput single cell imaging flow cytometry. RNA (2012) 0.79
Identification of the Essential Role of Viral Bcl-2 for Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication. J Virol (2015) 0.79
Laboratory diagnosis of human herpesvirus 8 infection in humans. Eur J Clin Microbiol Infect Dis (2002) 0.78
The activation of KSHV lytic cycle blocks autophagy in PEL cells. Autophagy (2015) 0.78
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol (1988) 12.84
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11
Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell (1996) 9.03
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science (1998) 7.89
Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol (1997) 7.71
Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A (1996) 6.00
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med (1996) 5.56
Primary structure of the herpesvirus saimiri genome. J Virol (1992) 5.26
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell (1987) 3.87
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A (1980) 3.77
Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J Clin Invest (1997) 3.71
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol (1998) 3.54
A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J Virol (1997) 3.10
Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry. J Virol (1998) 3.00
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open reading frame K8.1. J Virol (1998) 1.66
Identification and characterization of murine gammaherpesvirus 68 gp150: a virion membrane glycoprotein. J Virol (1996) 1.64
Interactions of murine gammaherpesvirus 68 with B and T cell lines. Virology (1993) 1.51
Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. J Virol (1993) 1.50
Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen. J Virol (1997) 1.47
Reactivities of human sera with human herpesvirus-8-infected BCBL-1 cells and identification of HHV-8-specific proteins and glycoproteins and the encoding cDNAs. Virology (1998) 1.37
Persistence of selectable herpesvirus saimiri in various human haematopoietic and epithelial cell lines. J Gen Virol (1991) 1.23
Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells. J Virol (1987) 1.13
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med (1995) 8.15
Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature (1987) 7.96
Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science (1985) 6.02
The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1990) 5.79
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 5.06
The Mex67p-mediated nuclear mRNA export pathway is conserved from yeast to human. EMBO J (1999) 4.49
Progression to AIDS in the absence of a gene for vpr or vpx. J Virol (1995) 3.96
Four novel U RNAs are encoded by a herpesvirus. Cell (1988) 3.86
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol (1996) 3.84
Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74
Significance of premature stop codons in env of simian immunodeficiency virus. J Virol (1989) 3.60
Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol (2000) 3.48
Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol (1991) 3.46
Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol (1989) 3.43
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40
Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol (2000) 3.31
Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol (2000) 3.30
Methylation of Herpesvirus saimiri DNA in lymphoid tumor cell lines. Proc Natl Acad Sci U S A (1979) 3.24
Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol (1987) 3.18
Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol (1992) 3.16
Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat Med (1997) 3.11
A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J Virol (1997) 3.10
The family Herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol (1992) 3.09
Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys. Cell (1995) 3.03
HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med (1999) 3.01
Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol (1998) 2.94
Stable growth transformation of human T lymphocytes by herpesvirus saimiri. Proc Natl Acad Sci U S A (1992) 2.94
Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med (2001) 2.90
Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol (1997) 2.90
Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses (1994) 2.72
Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J Virol (1993) 2.70
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol (1993) 2.65
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses (1994) 2.63
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Viral-encoded small RNAs in herpes virus saimiri induced tumors. EMBO J (1986) 2.60
Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol (1997) 2.57
Comparison of simian immunodeficiency virus isolates. Nature (1988) 2.55
Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity (2000) 2.53
Nononcogenic deletion mutants of herpesvirus saimiri are defective for in vitro immortalization. J Virol (1986) 2.52
A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J Virol (1997) 2.41
Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med (1998) 2.38
The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol (2001) 2.38
Cellular localization of simian immunodeficiency virus in lymphoid tissues. I. Immunohistochemistry and electron microscopy. Am J Pathol (1989) 2.33
Deletion mutants of herpesvirus saimiri define an open reading frame necessary for transformation. J Virol (1989) 2.29
The divergence between two oncogenic Herpesvirus saimiri strains in a genomic region related to the transforming phenotype. Virology (1990) 2.28
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol (1997) 2.27
Classification of herpesvirus saimiri into three groups based on extreme variation in a DNA region required for oncogenicity. J Virol (1984) 2.25
A region of the Herpesvirus saimiri genome required for oncogenicity. Science (1985) 2.22
A new type D retrovirus isolated from macaques with an immunodeficiency syndrome. Science (1984) 2.22
Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses (1994) 2.18
Identification of transforming genes of subgroup A and C strains of Herpesvirus saimiri. Proc Natl Acad Sci U S A (1991) 2.18
The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577. J Virol (2000) 2.15
Deletion of DNA sequence in a nononcogenic variant of Herpesvirus saimiri. J Virol (1984) 2.14
Herpesvirus saimiri DNA in a lymphoid cell line established by in vitro transformation. J Virol (1984) 2.09
Virus-encoded cyclin. Mol Cell Biol (1994) 2.06
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Characterization of Novikoff hepatoma mRNA methylation and heterogeneity in the methylated 5' terminus. Biochemistry (1975) 1.96
Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol (1998) 1.90
Construction of replication-competent Herpesvirus saimiri deletion mutants. J Virol (1984) 1.89
Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol (1998) 1.84
Identification and characterization of the herpesvirus saimiri oncoprotein STP-C488. J Virol (1991) 1.84
Herpesvirus saimiri strain variability. J Virol (1982) 1.80
Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS. J Virol (1993) 1.77
Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J Virol (1994) 1.77
Characterization of gut-associated lymphoid tissue (GALT) of normal rhesus macaques. Clin Immunol Immunopathol (1997) 1.74
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71
Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild. J Virol (1994) 1.70
A caution on the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses (1992) 1.70
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med (1999) 1.69
Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis. Am J Pathol (1996) 1.67
Association of the viral oncoprotein STP-C488 with cellular ras. Mol Cell Biol (1995) 1.66
Simian immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease progression. J Neurovirol (1998) 1.65
Sexual transmission of SIVagm in wild grivet monkeys. J Med Primatol (1994) 1.63
Simian immunodeficiency virus-induced meningoencephalitis: natural history and retrospective study. Ann Neurol (1988) 1.63
Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol (1998) 1.62
Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol Cell Biol (2000) 1.61
Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J Virol (2000) 1.57